A Randomized, Controlled, Double-Blind Phase 3 Study of Bevacizumab/Interferon-α2a vs Placebo/Interferon- α2a as First-line Therapy in Metastatic Renal Cell Carcinoma

Author Information

Contributors
First name and middle name First or given name, e.g. 'Peter'. Last Name Your last, or family, name, e.g. 'MacMoody'. Email Your email address, e.g. higgs-boson@gmail.com Role / Occupation Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.